Lupin is currently trading at Rs. 844.70, up by 3.60 points or 0.43% from its previous closing of Rs. 841.10 on the BSE.
The scrip opened at Rs. 858.00 and has touched a high and low of Rs. 863.90 and Rs. 843.00 respectively. So far 50341 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 906.35 on 27-Apr-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 880.00 and Rs. 811.30 respectively. The current market cap of the company is Rs. 38247.97 crore.
The promoters holding in the company stood at 46.93%, while Institutions and Non-Institutions held 38.99% and 13.80% respectively.
Lupin’s US based wholly owned subsidiary -- Lupin Pharmaceuticals Inc has declared positive top-line results from its pivotal Phase 3 clinical trial to assess efficacy and safety of single-dose Solosec (secnidazole) 2g oral granules in 147 female patients with trichomoniasis.
Trichomoniasis is the most common non-viral, curable, sexually transmitted infection (STI) in the US. The trial demonstrated a clinically and statistically significant response rate, or microbiological cure, in patients dosed with Solosec as compared to placebo (p<0.001).
Based on the data, the company plans to submit a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (USFDA) for Solosec for the treatment of trichomoniasis in the second half of 2020. Solosec is approved by the USFDA to treat bacterial vaginosis (BV) in adult women.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
